130250-54-3

Basic information

• Product Name: Ethyl 1-Boc-3-piperidinecarboxylate
• Synonyms: 1-(TERT-BUTOXYCARBONYL)-3-(ETHOXYCARBONYL)PIPERIDINE;ETHYL 1-BOC-3-PIPERIDINECARBOXYLATE;ETHYL N-BOC-NIPECOTATE;BOC-DL-NIPC-OET;BOC-DL-PIC(3)-EOT;BOC-DL-PIC(3)-OET;N-T-BUTOXYCARBONYL-DL-NIPECOTIC ACID ETHYL ESTER;N-T-BUTOXYCARBONYL-DL-PIPERIDINECARBOXYLIC ACID ETHYL ESTER
• CAS NO: 130250-54-3
• Molecular Formula: C₁₃H₂₃NO₄
• Molecular Weight: 257.32602
• EINECS: 1308068-626-2
• Product Categories: pharmacetical;Building Blocks;C13;Chemical Synthesis;Heterocyclic Building Blocks;Piperidines
• Mol File: 130250-54-3.mol

Chemical Properties

• Melting Point: 31-35℃
• Boiling Point: 95℃/0.5mm
• Flash Point: 149.7 °C
• Appearance: white crystalline power
• Density: 1.077 g/cm³
• Vapor Pressure: 0.000254mmHg at 25°C
• Refractive Index: 1.473
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -2.40±0.40(Predicted)
• Sensitive: Moisture & Light Sensitive
• BRN: 3614917
• CAS DataBase Reference: Ethyl 1-Boc-3-piperidinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 1-Boc-3-piperidinecarboxylate(130250-54-3)
• EPA Substance Registry System: Ethyl 1-Boc-3-piperidinecarboxylate(130250-54-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36-43-52
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 130250-54-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 1-Boc-3-piperidinecarboxylate is used as a reactant for the synthesis of GABAA receptor agonists, which play a crucial role in the central nervous system by enhancing the effects of the inhibitory neurotransmitter GABA, leading to sedation, hypnotic, and anticonvulsant effects.
Used in Organic Synthesis:
Ethyl 1-Boc-3-piperidinecarboxylate is used as a reactant for the synthesis of piperidine derivatives, which are important building blocks in the development of various pharmaceuticals, agrochemicals, and other organic compounds.
Used in Enzyme Inhibition:
Ethyl 1-Boc-3-piperidinecarboxylate is used as a reactant for the synthesis of selective TACE (tumor necrosis factor-alpha converting enzyme) inhibitors, which have potential applications in the treatment of inflammatory and autoimmune diseases by regulating the production of pro-inflammatory cytokines.
Used in Cardiovascular Applications:
Ethyl 1-Boc-3-piperidinecarboxylate is used as a reactant for the synthesis of HDL-elevating agents, which can help increase the levels of high-density lipoprotein (HDL) cholesterol, often referred to as "good" cholesterol, and contribute to the management of cardiovascular health.
Used in Metal Chelation:
Ethyl 1-Boc-3-piperidinecarboxylate is used as a reactant for the synthesis of α-sulfonyl hydroxamic acid derivatives, which have potential applications as metal-chelating agents, useful in various industrial and environmental processes.
Used in Alkaloid Synthesis:
Ethyl 1-Boc-3-piperidinecarboxylate is used as a reactant for the synthesis of chemicals in the Iboga-alkaloid family, which have potential applications in the development of treatments for addiction and neurodegenerative disorders.

InChI:InChI=1/C13H23NO4/c1-5-17-11(15)10-7-6-8-14(9-10)12(16)18-13(2,3)4/h10H,5-9H2,1-4H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 71962-74-8 Ethyl nipecotate 
• 4842-86-8 ethyl piperidine-3-carboxylate hydrochloride 

Downstream Products

• 91419-49-7 tert-butyl 3-carbamoylpiperidine-1-carboxylate 
• 71381-75-4 N-(tert-butyloxycarbonyl)nipecotic acid 
• 170842-80-5 3-Benzylpiperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 170844-67-4 3-pyridin-2-ylmethyl-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 1624302-00-6 1-tert-butyl 3-ethyl 3-methyl piperidine-1,3,3-tricarboxylate 
• 116574-71-1 (±)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate 
• 278789-43-8 ethyl N-t-butyloxycarbonyl-3-methylpiperidine-3-carboxylate 
• 934270-61-8 3-benzyl-5-[(tert-butoxycarbonyl)piperidin-3-yl]-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-ol 
• 934270-60-7 5-[(tert-butoxycarbonyl)piperidin-3-yl]-3-(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-ol 
• 934270-63-0 5-[(tert-butoxycarbonyl)piperidin-3-yl]-3-(4-fluorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-ol 
• 884512-51-0 tert-butyl 3-(2,2,2-trifluoroacetyl)piperidine-1-carboxylate 
• 948589-00-2 1-tert-butyl 3-ethyl 3-(iodomethyl)piperidine-1,3-dicarboxylate 
• 948589-03-5 1-(tert-butyl) 3-ethyl 3-{[4-(2-butynyloxy)phenyl]sulfonyl}-1,3-piperidine dicarboxylate 
• 948589-04-6 C₁₉H₂₅NO₅S 

Relevant articles and documents

SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY

In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dysregulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

PYRAZOLOPYRIDAZINE DERIVATIVES, PREPARATION METHOD THEREOF AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME

The present invention is a pyrazolopyridazine derivative. A pharmaceutical composition for preventing or treating cancer contains the pyrazolopyridazin derivative compound Hsp90 according to the present invention as an active ingredient, which can be used as Hsp90 a pharmaceutical composition for preventing or treating Hsp90-related diseases such as melanoma, brain tumor, breast cancer, lung cancer and the like. (by machine translation)

PHARMACEUTICAL COMPOUNDS

This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Discovery, synthesis, biological evaluation and structure-based optimization of novel piperidine derivatives as acetylcholine-binding protein ligands

The homomeric α7 nicotinic receptor (α7 nAChR) is widely expressed in the human brain that could be activated to suppress neuroinflammation, oxidative stress and neuropathic pain. Consequently, a number of α7 nAChR agonists have entered clinical trials as

Design and synthesis of novel spiro-piperidinyl pyrazolone derivatives and their potential antiviral activity

A series of novel spiro-piperidinyl pyrazolones were synthesized starting from the commercially available ethyl nipecotate. The Boc protected ethyl nipecotate was reacted with 5-bromo-2-furaldehyde in the presence of LDA to afford the β -hydroxy ester whi

COGNITION ENHANCING COMPOUNDS AND COMPOSITIONS, METHODS OF MAKING, AND METHODS OF TREATING

The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine, receptors and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans. The compositions comprising a muscarinic agonist or a pharma.ceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.

COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING

Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further disclosed are methods for treating a subject with said muscarinic agonists or a pharmaceutically suitable form thereof to enhance cognitive function.

COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING

Muscarinic agonists, which are useful for stimulating muscarinic receptors and treating cognitive disorders, are provided. Methods of synthesizing such agonists also are provided. Also provided are compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. Also provided are methods of treating animals such as humans by administering such compositions.

Synthesis of 3-(3-piperidyl)-isoquinoline and 3-(4-piperidyl)-isoquinoline

3-(3-Piperidyl)isoquinoline and 3-(4-piperidyl)isoquinoline have been synthesized from o-tolylaldehyde aldimines and the methylmethoxycarboxamides (Weinreb amides) of N-Boc-substituted nipecotic and isonipecotic acids.